Polymeric micelles for GSH-triggered delivery of arsenic species to cancer cells

Biomaterials

Volumn 35, Issue 25, 2014, Pages 7088-7100

  Zhang, Qi ^a   Vakili, Mohammad Reza ^a   Li, Xing Fang ^a   Lavasanifar, Afsaneh ^a   Le, X Chris ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Arsenic; Drug delivery; Poly(ethylene oxide) b poly( carboxylate caprolactone); Polymeric micelles

Indexed keywords

ARSENIC; CARBOXYLATION; DRUG DELIVERY; DYNAMIC LIGHT SCATTERING; FUNCTIONAL POLYMERS; INDUCTIVELY COUPLED PLASMA MASS SPECTROMETRY; LOADING; MICELLES; POLYETHYLENE OXIDES; TUMORS;

BIODEGRADABLE BLOCK COPOLYMERS; CAPROLACTONE; CHEMOTHERAPEUTIC AGENTS; DRUG DELIVERY SYSTEM; INDUCTIVELY COUPLED PLASMA MASS SPECTROMETRIES (ICPMS); POLYMERIC MICELLE; PROMYELOCYTIC LEUKEMIA; TUMOR-TARGETED DRUG DELIVERIES;

BIODEGRADABLE POLYMERS;

ARSENIC TRIOXIDE; ARSENOSOBENZENE; COPOLYMER; GLUTATHIONE; POLYCAPROLACTONE; THIOL GROUP; WATER; ANTINEOPLASTIC AGENT; CAPROLACTAM; MACROGOL DERIVATIVE; METHOXY POLY(ETHYLENE OXIDE)-BLOCK-POLY(ALPHA-(6-MECAPTOHEXYL AMINO)CARBOXYLATE-EPSILON-CAPROLACTONE); MICELLE; ORGANOARSENIC DERIVATIVE; OXIDE; POLYMER;

ARTICLE; CANCER CELL; CANCER THERAPY; CELL LINE; CIRCULATION; CONJUGATION; CONTROLLED DRUG RELEASE; DRUG ACCUMULATION; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; ENCAPSULATION; HUMAN; HUMAN CELL; HYDROPHOBICITY; IC 50; IN VITRO STUDY; LIGHT SCATTERING; MASS SPECTROMETRY; MICELLE; PARTICLE SIZE; POLYMERIZATION; PRIORITY JOURNAL; SOLID TUMOR; ANALOGS AND DERIVATIVES; CHEMISTRY; IC50; PROCEDURES; SYNTHESIS; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; ARSENICALS; CAPROLACTAM; CELL LINE, TUMOR; DRUG DELIVERY SYSTEMS; GLUTATHIONE; HUMANS; INHIBITORY CONCENTRATION 50; MICELLES; OXIDES; POLYETHYLENE GLYCOLS; POLYMERS;

EID: 84902077776     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2014.04.072     Document Type: Article

References (54)

1. Zhu J., Chen Z., Lallemand-Breitenbach V., de Thé H. How acute promyelocytic leukaemia revived arsenic. Nat Rev Cancer 2002, 2:705-713.
2. Leu L., Mohassel L. Arsenic trioxide as first-line treatment for acute promyelocytic leukemia. Am J Health Syst Pharm 2009, 66:1913-1918.
3. 3) in the treatment of acute promyelocytic leukemia (APE). 2. Clinical efficacy and pharmacokinetics in relapsed patients. Blood 1997, 89:3354-3360.
4. Niu C., Yan H., Yu T., Sun H.P., Liu J.X., Li X.S., et al. Studies on treatment of acute promyelocytic leukemia with arsenic trioxide: remission induction, follow-up, and molecular monitoring in 11 newly diagnosed and 47 relapsed acute promyelocytic leukemia patients. Blood 1999, 94:3315-3324.
5. Hu J., Liu Y.-F., Wu C.-F., Xu F., Shen Z.-X., Zhu Y.-M., et al. Long-term efficacy and safety of all-trans retinoic acid/arsenic trioxide-based therapy in newly diagnosed acute promyelocytic leukemia. Proc Natl Acad Sci U S A 2009, 106:3342-3347.
6. de Botton S., Coiteux V., Chevret S., Rayon C., Vilmer E., Sanz M., et al. Outcome of childhood acute promyelocytic leukemia with all-trans-retinoic acid and chemotherapy. JClin Oncol 2004, 22:1404-1412.
7. Zhou J., Zhang Y.M., Li J.M., Li X.X., Hou J.X., Zhao Y.Q., et al. Single-agent arsenic trioxide in the treatment of children with newly diagnosed acute promyelocytic leukemia. Blood 2010, 115:1697-1702.
8. Zhu J., Koken M.H.M., Quignon F., Chelbi-Alix M.K., Degos L., Wang Z.Y., et al. Arsenic-induced PML targeting onto nuclear bodies: implications for the treatment of acute promyelocytic leukemia. Proc Natl Acad Sci U S A 1997, 94:3978-3983.
9. Lallemand-Breitenbach V., Jeanne M., Benhenda S., Nasr R., Lei M., Peres L., et al. Arsenic degrades PML or PML-RAR alpha through a SUMO-triggered RNF4/ubiquitin-mediated pathway. Nat Cell Biol 2008, 10:547-555.
10. Zhang X.W., Yan X.J., Zhou Z.R., Yang F.F., Wu Z.Y., Sun H.B., et al. Arsenic trioxide controls the fate of the PML-RAR alpha oncoprotein by directly binding PML. Science 2010, 328:240-243.
11. Ablain J., de Thé H. Revisiting the differentiation paradigm in acute promyelocytic leukemia. Blood 2011, 117:5795-5802.
12. Nasr R., Guillemin M.C., Ferhi O., Soilihi H., Peres L., Berthier C., et al. Eradication of acute promyelocytic leukemia-initiating cells through PML-RARα degradation. Nat Med 2008, 14:1333-1342.
13. 3 exerts dose-dependent dual effects on APL cells. Blood 1997, 89:3345-3353.
14. Wang S.S., Zhang T., Wang X.L., Hong L., Qi Q.H. Effect of arsenic trioxide on rat hepatocarcinoma and its renal cytotoxicity. World J Gastroenterol 2003, 9:930-935.
15. Li X.Q., Ding X.Z., Adrian T.E. Arsenic trioxide causes redistribution of cell cycle, caspase activation, and GADD expression in human colonic, breast, and pancreatic cancer cells. Cancer Invest 2004, 22:389-400.
16. 3) inhibits expression of estrogen receptor-alpha through regulation of the mitogen-activated protein kinase (MAPK) pathway in endometrial cancer cells. Reprod Sci 2008, 15:1011-1017.
17. Tarhini A.A., Kirkwood J.M., Tawbi H., Gooding W.E., Islam M.F., Agarwala S.S. Safety and efficacy of arsenic trioxide for patients with advanced metastatic melanoma. Cancer 2008, 112:1131-1138.
18. Dilda P.J., Hogg P.J. Arsenical-based cancer drugs. Cancer Treat Rev 2007, 33:542-564.
19. Maeda H., Hori S., Ohizumi H., Segawa T., Kakehi Y., Ogawa O., et al. Effective treatment of advanced solid tumors by the combination of arsenic trioxide and L-buthionine-sulfoximine. Cell Death Differ 2004, 11:737-746.
20. Lin L.M., Li B.X., Xiao J.B., Lin D.H., Yang B.F. Synergistic effect of all-trans-retinoic acid and arsenic trioxide on growth inhibition and apoptosis in human hepatoma, breast cancer, and lung cancer cells invitro. World J Gastroenterol 2005, 11:5633-5637.
21. 2 (a novel, noncalcemic vitamin D analogue), combined with arsenic trioxide, has potent antitumor activity against myeloid leukemia. Cancer Res 2005, 65:2488-2497.
22. Diaz Z., Laurenzana A., Mann K.K., Bismar T.A., Schipper H.M., Miller W. Trolox enhances the anti-lymphoma effects of arsenic trioxide, while protecting against liver toxicity. Leukemia 2007, 21:2117-2127.
23. Barreto J.A., O'Malley W., Kubeil M., Graham B., Stephan H., Spiccia L. Nanomaterials: applications in cancer imaging and therapy. Adv Mater 2011, 23:H18-H40.
24. Fang J.Y., Al-Suwayeh S.A. Nanoparticles as delivery carriers for anticancer prodrugs. Expert Opin Drug Deliv 2012, 9:657-669.
25. Kallinteri P., Fatouros D., Klepetsanis P., Antimisiaris S.G. Arsenic trioxide liposomes: encapsulation efficiency and invitro stability. JLiposome Res 2004, 14:27-38.
26. Zagana P., Haikou M., Klepetsanis P., Giannopoulou E., Ioannou P.V., Antimisiaris S.G. Invivo distribution of arsonoliposomes: effect of vesicle lipid composition. Int J Pharm 2008, 347:86-92.
27. Chen H.M., MacDonald R.C., Li S.Y., Krett N.L., Rosen S.T., O'Halloran T.V. Lipid encapsulation of arsenic trioxide attenuates cytotoxicity and allows for controlled anticancer drug release. JAm Chem Soc 2006, 128:13348-13349.
28. Chen H., Ahn R., Van den Bossche J., Thompson D.H., O'Halloran T.V. Folate-mediated intracellular drug delivery increases the anticancer efficacy of nanoparticulate formulation of arsenic trioxide. Mol Cancer Ther 2009, 8:1955-1963.
29. Winter N.D., Murphy R.K.J., O'Halloran T.V., Schatz G.C. Development and modeling of arsenic trioxide-loaded thermosensitive liposomes for anticancer drug delivery. JLiposome Res 2011, 21:106-115.
30. Ahn R.W., Chen F., Chen H.M., Stern S.T., Clogston J.D., Patri A.K., et al. Anovel nanoparticulate formulation of arsenic trioxide with enhanced therapeutic efficacy in a murine model of breast cancer. Clin Cancer Res 2010, 16:3607-3617.
31. Yang Z.W., Yang M.H., Peng J.A. Evaluation of arsenic trioxide-loaded albumin nanoparticles as carriers: preparation and antitumor efficacy. Drug Dev Ind Pharm 2008, 34:834-839.
32. Wang Z.Q., Liu W., Xu H.B., Yang X.L. Preparation and invitro studies of stealth PEGylated PLGA nanoparticles as carriers for arsenic trioxide. Chin J Chem Eng 2007, 15:795-801.
33. Shin I.L.G., Kim S.Y., Lee Y.M., Cho C.S., Sung Y.K. Methoxy poly(ethylene glycol) epsilon-caprolactone amphiphilic block copolymeric micelle containing indomethacin. I. Preparation and characterization. JControl Release 1998, 51:1-11.
34. Liu J.B., Zeng F.Q., Allen C. Invivo fate of unimers and micelles of a poly(ethylene glycol)-block-poly(caprolactone) copolymer in mice following intravenous administration. Eur J Pharm Biopharm 2007, 65:309-319.
35. Armarego W.L.F., Chai C. Purification of laboratory chemicals 2009, Butterworth-Heinemann, Elsevier, Oxford. 6th ed.
36. Xiong X.B., Mahmud A., Uludag H., Lavasanifar A. Multifunctional polymeric micelles for enhanced intracellular delivery of doxorubicin to metastatic cancer cells. Pharm Res 2008, 25:2555-2566.
37. Mahmud A., Xiong X.B., Lavasanifar A. Novel self-associating poly(ethylene oxide)-block-poly(epsilon-caprolactone) block copolymers with functional side groups on the polyester block for drug delivery. Macromolecules 2006, 39:9419-9428.
38. Ellman G.L. Tissue sulfhydryl groups. Arch Biochem Biophys 1959, 82:70-77.
39. Thannhauser T.W., Konishi Y., Scheraga H.A. Sensitive quantitative-analysis of disulfide bonds in polypeptides and proteins. Anal Biochem 1984, 138:181-188.
40. Thannhauser T.W., Konishi Y., Scheraga H.A. Analysis for disulfide bons in peptides and proteins. Methods Enzymol 1987, 143:115-119.
41. Ohyashiki T., Mohri T. Fluorometric analysis of the micelle formation process of surfactants in aqueous-solution. 1. Utility of pyrene in determination of the critical micelle concentration. Chem Pharm Bull 1983, 31:1296-1300.
42. Wilhelm M., Zhao C.L., Wang Y.C., Xu R.L., Winnik M.A., Mura J.L., et al. Polymer micelle formation. 3. poly(styrene-ethylene oxide) block copolymer micelle formation in water - a fluorescence probe study. Macromolecules 1991, 24:1033-1040.
43. Shahin M., Lavasanifar A. Novel self-associating poly(ethylene oxide)-b-poly(epsilon-caprolactone) based drug conjugates and nano-containers for paclitaxel delivery. Int J Pharm 2010, 389:213-222.
44. Goddard E.D. Polymer surfactant interaction. 1. Uncharged water-soluble polymers and charged surfactants. Colloid Surf 1986, 19:255-300.
45. Shen S., Li X., Cullen W., Weinfeld M., Le X. Arsenic binding to proteins. Chem Rev 2013, 113:7769-7792.
46. Haas R., Krippendorf A. Determination of chemical warfare agents in soil and material samples - gas chromatographic analysis of phenylarsenic compounds (sternutators) (1st communication). Environ Sci Pollut Res 1997, 4:123-124.
47. Kroening K.K., Solivio M.J.V., Garcia-Lopez M., Puga A., Caruso J.A. Cytotoxicity of arsenic-containing chemical warfare agent degradation products with metallomic approaches for metabolite analysis. Metallomics 2009, 1:59-66.
48. Kondo S., Mori H., Sasai Y., Kuzuya M. Conventional synthesis of amphiphilic block copolymer utilized for polymeric micelle by mechanochemical solid-state polymerization. Chem Pharm Bull 2007, 55:389-392.
49. Hsu Y.H., Chiang W.H., Chen M.C., Chern C.S., Chiu H.C. Effects of SDS on the thermo- and pH-sensitive structural changes of the poly(acrylic acid)-based copolymer containing both poly(N-isopropylacrylamide) and monomethoxy poly(ethylene glycol) grafts in water. Langmuir 2006, 22:6764-6770.
50. Vangeyte P., Leyh B., Auvray L., Grandjean J., Misselyn-Bauduin A.M., Jerome R. Mixed self-assembly of poly(ethylene oxide)-b-poly(epsilon-caprolactone) copolymers and sodium dodecyl sulfate in aqueous solution. Langmuir 2004, 20:9019-9028.
51. Wu G.Y., Fang Y.Z., Yang S., Lupton J.R., Turner N.D. Glutathione metabolism and its implications for health. JNutr 2004, 134:489-492.
52. Griffith O.W. Biologic and pharmacologic regulation of mammalian glutathione synthesis. Free Radic Biol Med 1999, 27:922-935.
53. Richie J.P., Skowronski L., Abraham P., Leutzinger Y. Blood glutathione concentrations in a large-scale human study. Clin Chem 1996, 42:64-70.
54. Jeitner T.M., Lawrence D.A. Mechanisms for the cytotoxicity of cysteamine. Toxicol Sci 2001, 63:57-64.